Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. NeuroMetrix, Inc.
  6. Summary
    NURO   US6412558073

NEUROMETRIX, INC.

(NURO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
9.43(c) 9.67(c) 9.24(c) 8.94(c) 9(c) Last
600 209 568 121 536 627 393 949 446 478 Volume
+5.96% +2.55% -4.45% -3.25% +0.67% Change
More quotes
Estimated financial data (e) (USD)
Sales 2019 9,27 M - -
Net income 2019 -3,77 M - -
Net cash position 2019 1,62 M - -
P/E ratio 2019 -1,10x
Yield 2019 -
Sales 2020 7,38 M - -
Net income 2020 -2,09 M - -
Net cash position 2020 4,17 M - -
P/E ratio 2020 -4,55x
Yield 2020 -
Capitalization 50,7 M 50,7 M -
EV / Sales 2019 0,28x
EV / Sales 2020 1,06x
Nbr of Employees 20
Free-Float 99,4%
More Financials
Company
NeuroMetrix, Inc. develops and commercializes health care products that utilize non-invasive neurostimulation. The Company is engaged in the designing, building and marketing of medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. It has two principal product categories, which includes point-of-care neuropathy diagnostic tests and wearable neurostimulation devices. 
More about the company
All news about NEUROMETRIX, INC.
10/14NeuroMetrix, Inc. Announces Date for Third Quarter 2021 Financial Results Conference Ca..
GL
10/07NeuroMetrix Shares Rise 10% After Submitting De Novo Request for Quell
DJ
10/07NEUROMETRIX : Announces Submission of FDA De Novo Request for Treatment of Fibromyalgia Sy..
AQ
10/07NEUROMETRIX : Files for FDA De Novo Clearance for Quell Device to Treat Symptoms of Fibrom..
MT
10/06NeuroMetrix Announces Submission of FDA De Novo Request for Treatment of Fibromyalgia S..
GL
10/06NeuroMetrix Announces Submission of U.S. Food and Drug Administration De Novo Request f..
CI
10/05NEUROMETRIX : Announces Participation in the Center to Stream Healthcare In Place (C2SHIP)..
AQ
08/27Top Premarket Gainers
MT
08/13INSIDER TRENDS : Insider Sale at NeuroMetrix Scaling Back 90-Days of Buying
MT
08/13NEUROMETRIX : Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in ..
PU
08/13NEUROMETRIX, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/26NEUROMETRIX : Announces Peer-Reviewed Publication of a Randomized Controlled Trial of its ..
AQ
07/22NEUROMETRIX : Q2 Loss Narrows as Revenue Climbs
MT
07/22NEUROMETRIX : Management's Discussion and Analysis of Financial Condition and Results of O..
AQ
07/22Wall Street Wavers Pre-Bell as Jobless Claims Rise
MT
More news
News in other languages on NEUROMETRIX, INC.
10/07NeuroMetrix dépose une demande d'autorisation de novo auprès de la FDA pour le disposit..
More news
Chart NEUROMETRIX, INC.
Duration : Period :
NeuroMetrix, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEUROMETRIX, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Managers and Directors
Shai N. Gozani Chairman, President & Chief Executive Officer
Thomas T. Higgins Chief Financial Officer, Treasurer & Senior VP
David E. Goodman Independent Director
Nancy E. Katz Independent Director
David van Avermaete Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NEUROMETRIX, INC.184.81%51
ABBOTT LABORATORIES7.31%208 288
MEDTRONIC PLC9.06%171 927
BECTON, DICKINSON AND COMPANY-3.62%69 259
HOYA CORPORATION20.71%55 655
DEXCOM, INC.47.27%52 677